Cargando…
Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
SIMPLE SUMMARY: Advanced prostate cancer remains a clinical challenge, requiring novel therapeutic treatments and biomarkers for patient-risk stratification. From a metabolic perspective, primary prostate cancer shows unique features with respect to most solid tumors, being mainly characterized by a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340474/ https://www.ncbi.nlm.nih.gov/pubmed/37444583 http://dx.doi.org/10.3390/cancers15133473 |
_version_ | 1785072088307990528 |
---|---|
author | Chetta, Paolo Sriram, Renuka Zadra, Giorgia |
author_facet | Chetta, Paolo Sriram, Renuka Zadra, Giorgia |
author_sort | Chetta, Paolo |
collection | PubMed |
description | SIMPLE SUMMARY: Advanced prostate cancer remains a clinical challenge, requiring novel therapeutic treatments and biomarkers for patient-risk stratification. From a metabolic perspective, primary prostate cancer shows unique features with respect to most solid tumors, being mainly characterized by an oxidative/lipogenic phenotype. However, increased aerobic glycolysis with enhanced lactate production (Warburg effect) is frequently observed in high-risk disease and during the onset of castration resistance. In this review, we summarize the key role of lactate in prostate cancer progression. We also highlight the clinical implication of lactate as a predictive/prognostic biomarker and the therapeutic potential of targeting lactate metabolism in prostate cancer. ABSTRACT: Advanced prostate cancer represents the fifth leading cause of cancer death in men worldwide. Although androgen-receptor signaling is the major driver of the disease, evidence is accumulating that disease progression is supported by substantial metabolic changes. Alterations in de novo lipogenesis and fatty acid catabolism are consistently reported during prostate cancer development and progression in association with androgen-receptor signaling. Therefore, the term “lipogenic phenotype” is frequently used to describe the complex metabolic rewiring that occurs in prostate cancer. However, a new scenario has emerged in which lactate may play a major role. Alterations in oncogenes/tumor suppressors, androgen signaling, hypoxic conditions, and cells in the tumor microenvironment can promote aerobic glycolysis in prostate cancer cells and the release of lactate in the tumor microenvironment, favoring immune evasion and metastasis. As prostate cancer is composed of metabolically heterogenous cells, glycolytic prostate cancer cells or cancer-associated fibroblasts can also secrete lactate and create “symbiotic” interactions with oxidative prostate cancer cells via lactate shuttling to sustain disease progression. Here, we discuss the multifaceted role of lactate in prostate cancer progression, taking into account the influence of the systemic metabolic and gut microbiota. We call special attention to the clinical opportunities of imaging lactate accumulation for patient stratification and targeting lactate metabolism. |
format | Online Article Text |
id | pubmed-10340474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103404742023-07-14 Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? Chetta, Paolo Sriram, Renuka Zadra, Giorgia Cancers (Basel) Review SIMPLE SUMMARY: Advanced prostate cancer remains a clinical challenge, requiring novel therapeutic treatments and biomarkers for patient-risk stratification. From a metabolic perspective, primary prostate cancer shows unique features with respect to most solid tumors, being mainly characterized by an oxidative/lipogenic phenotype. However, increased aerobic glycolysis with enhanced lactate production (Warburg effect) is frequently observed in high-risk disease and during the onset of castration resistance. In this review, we summarize the key role of lactate in prostate cancer progression. We also highlight the clinical implication of lactate as a predictive/prognostic biomarker and the therapeutic potential of targeting lactate metabolism in prostate cancer. ABSTRACT: Advanced prostate cancer represents the fifth leading cause of cancer death in men worldwide. Although androgen-receptor signaling is the major driver of the disease, evidence is accumulating that disease progression is supported by substantial metabolic changes. Alterations in de novo lipogenesis and fatty acid catabolism are consistently reported during prostate cancer development and progression in association with androgen-receptor signaling. Therefore, the term “lipogenic phenotype” is frequently used to describe the complex metabolic rewiring that occurs in prostate cancer. However, a new scenario has emerged in which lactate may play a major role. Alterations in oncogenes/tumor suppressors, androgen signaling, hypoxic conditions, and cells in the tumor microenvironment can promote aerobic glycolysis in prostate cancer cells and the release of lactate in the tumor microenvironment, favoring immune evasion and metastasis. As prostate cancer is composed of metabolically heterogenous cells, glycolytic prostate cancer cells or cancer-associated fibroblasts can also secrete lactate and create “symbiotic” interactions with oxidative prostate cancer cells via lactate shuttling to sustain disease progression. Here, we discuss the multifaceted role of lactate in prostate cancer progression, taking into account the influence of the systemic metabolic and gut microbiota. We call special attention to the clinical opportunities of imaging lactate accumulation for patient stratification and targeting lactate metabolism. MDPI 2023-07-03 /pmc/articles/PMC10340474/ /pubmed/37444583 http://dx.doi.org/10.3390/cancers15133473 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chetta, Paolo Sriram, Renuka Zadra, Giorgia Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? |
title | Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? |
title_full | Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? |
title_fullStr | Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? |
title_full_unstemmed | Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? |
title_short | Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications? |
title_sort | lactate as key metabolite in prostate cancer progression: what are the clinical implications? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340474/ https://www.ncbi.nlm.nih.gov/pubmed/37444583 http://dx.doi.org/10.3390/cancers15133473 |
work_keys_str_mv | AT chettapaolo lactateaskeymetaboliteinprostatecancerprogressionwhataretheclinicalimplications AT sriramrenuka lactateaskeymetaboliteinprostatecancerprogressionwhataretheclinicalimplications AT zadragiorgia lactateaskeymetaboliteinprostatecancerprogressionwhataretheclinicalimplications |